Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET.

Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024

MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Shawn M. Leland, PharmD, RPh, will participate in a fireside chat at the Cantor Global Healthcare Conference 2024 on Tuesday, September 17, 2024 at 8:00 a.m. Eastern Daylight Time / 14:00 Central European Time.

Affimed to Present at the Cantor Global Healthcare Conference 2024

Affimed N.V. (NASDAQ:AFMD ) Q2 2024 Earnings Conference Call September 5, 2024 8:30 AM ET Company Participants Alex Fudukidis - Head, Investor Relations Shawn Leland - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Michael Wolf - Vice President, Finance Conference Call Participants Maury Raycroft - Jefferies Daina Graybosch - Leerink Partners Bill Jahangiri - Truist Securities Li Watsek - Cantor Brad Canino - Stifel Swayampakula Ramakanth - H.C.

Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript

MANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended June 30, 2024.

Affimed Reports Second Quarter 2024 Financial Results & Business Update

On 06/11/24, I published an article on Affimed focused on my belief the company's upcoming acimtamig update would be positive. It was, and Affimed's stock popped the next day. The stock has since dropped to below $4/s based, in my opinion, on investor's perceptions that a dilutive capital raise is coming soon. AFMD's 2Q '24 Earnings Call is scheduled for tomorrow, 09/05/24. And we are due for an acimtamig and AFM24 3Q '24 update before the end of the month.

Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts

AFMD appoints Shawn M. Leland as the company's new chief executive officer.

Affimed Appoints New CEO, Shares Fall on Leadership Change

MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO).

Affimed Appoints Shawn M. Leland as Chief Executive Officer

MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2024 results and corporate update on Thursday, September 5, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

Affimed N.V. (NASDAQ:AFMD ) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – VP, Finance Conference Call Participants Srikripa Devarakonda - Truist Securities Daina Graybosch - Leerink Partners Maury Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Bradley Canino - Stifel, Nicolaus & Company Operator Good day, everyone and welcome to Affimed's First Quarter 2024 Earnings and Corporate Update Call.

Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset.  This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month.  If it is positive, the stock should run again for a possible 3-5x. Although the company will likely raise capital after the announcement, I am comfortable owning shares into the action and I am a fan now for the longer term.

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a study The FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 study Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need Company to host a conference call / webcast on June 1, 2024 at 7:00 p.m. EDT to discuss the updated data from the AFM24-102 trial MANNHEIM, Germany, May 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V.

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.

Affimed Announces Annual General Meeting of Shareholders

Anixa Biosciences Inc

FibroGen

Genenta Science S.P.A.

Lipocine

Nuvectis Pharma

Relmada Therapeutics Inc

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.

7 Penny Biotech Stocks to Triple Your Investment

MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company's AFM24-102 study in advanced EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago on May 31 – June 4, 2024. Patients in the study are treated with the combination of AFM24, Affimed's innate cell engager (ICE®), and atezolizumab, Roche's checkpoint inhibitor (CPI).

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Bitdeer Technologies Group

Clean Energy Fuels

Many analysts forecast that an interest rate cut is coming by September. When that happens, speculative capital is likely to move away from large-cap stocks.

Small-Cap Sensations: 3 Stocks Under $10 With 10X Potential

MANNHEIM, Germany, May 14, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the publication of an abstract for the annual congress of the European Hematology Association (EHA), taking place in Madrid, Spain, June 13 – 16, 2024. The abstract presents preclinical data of Affimed's CD16A/CD123-targeting ICE®, AFM28, in an acute myeloid leukemia (AML) mouse xenograft model and shows that increasing doses of AFM28 lead to a dose-dependent tumor growth control, resulting in an increased median life span of the treated mice compared to controls.

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

The consensus price target hints at a 146.7% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to Trade

MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an abstract presenting preliminary data from the phase 2 combination study of AFM24, its innate cell engager (ICE®), in combination with atezolizumab, Roche's checkpoint inhibitor, in patients with EGFR-wildtype (EGFRwt) non-small cell lung cancer (NSCLC) has been accepted for poster presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

After losing some value lately, a hammer chart pattern has been formed for Affimed N.V. (AFMD), indicating that the stock has found support.

Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Affimed Stock (AFMD)